10 important studies you may have missed from San Antonio Breast Cancer Symposium

In In The News by Barbara Jacoby

From: healio.com

Healio provided comprehensive coverage of this year’s San Antonio Breast Cancer Symposium.

Content includes stories about potentially practice-changing research, as well as perspective from key opinion leaders who discuss the implications of the findings.

Here are 10 important studies from the symposium that may be relevant to your practice:

  1. Elacestrant (Radius Health) improved outcomes compared with standard endocrine therapy for certain women with pretreated ER-positive, HER2-negative metastatic breast cancer. Read more.
  2. Black and Hispanic women appeared more likely than white women to develop breast cancer-related lymphedema. Black race appeared to be the strongest predictor of lymphedema development and severity. Read more.
  3. Use of genomics to guide treatment selection improved outcomes for certain patients with metastatic breast cancer. Researchers observed the greatest benefit with the multigene sequencing strategy when the genomic alterations identified were included in the top two tiers of the ESMO Scale for Clinical Actionability of Molecular Targets. Read more.
  4. A liquid biopsy-based approach to treatment selection improved outcomes among patients with hormone receptor-positive, HER2-negative metastatic breast cancer. Patients treated with an aromatase inhibitor plus the cyclin-dependent kinase 4/6 inhibitor palbociclib (Ibrance, Pfizer) who displayed a rising ESR1 mutation in their blood prior to disease progression doubled their median PFS if they switched to fulvestrant plus palbociclib rather than remaining on the same regimen. Read more.
  5. Nivolumab (Opdivo, Bristol Myers Squibb) plus ipilimumab (Yervoy, Bristol Myers Squibb) induced durable responses among a small cohort of women with high tumor mutational burden metastatic HER2-negative breast cancer. Read more.
  6. Aromatase inhibitors may reduce breast cancer recurrence compared with tamoxifen for certain premenopausal women with breast cancer. Read more.
  7. Patients with breast cancer who developed tamoxifen-associated uterine cancer had fewer phosphatidylinositol 3-kinase pathway mutations than those with de novo cases. This finding suggests these cancers may have been driven by tamoxifen-induced activation of the phosphatidylinositol 3-kinase pathway. Read more.
  8. Race did not significantly predict response to treatment outcomes among women with high-risk breast cancer. Results showed tumor biology more strongly predicted pathologic complete response, EFS and other outcomes. Read more.
  9. Imaging mass cytometry appeared feasible and allowed for a more comprehensive overview of triple-negative breast cancer heterogeneity at a single-cell level. The next-generation technology also provided insights into the value of adding atezolizumab (Tecentriq, Genentech) to neoadjuvant chemotherapy for patients with early high-risk and locally advanced triple-negative breast cancer. Read more.
  10. Pyrotinib (Hengrui Therapeutics) plus capecitabine prolonged OS and PFS compared with lapatinib (Tykerb, Novartis) and capecitabine among patients with pretreated HER2-positive metastatic breast cancer. Read more.